VKTX stock forecast, quote, news & analysis
Viking Therapeutics Inc is a healthcare service provider... Show more
Why Viking Therapeutics (VKTX) Stock Is Down -12% in the Last 30 Days
Key Takeaways
- VKTX fell roughly 12% over the past 30 days, even after a one-day surge of more than 35% on positive VK2735 maintenance-dosing data.
- A $35-per-share equity offering and concurrent convertible notes deal, upsized to roughly $575 million in gross proceeds, pressured the stock after the initial rally.
- Over the last quarter, the stock declined approximately 31% as the post-data spike faded.
- Investor attention remains fixed on the VK2735 obesity program, including Phase 3 subcutaneous and oral trials.
- Analysts have called the maintenance data a "best-case scenario," but dilution and a crowded obesity market have weighed on sentiment.
Viking Therapeutics (VKTX) Company Overview and Market Position
Viking Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for obesity and metabolic disorders. Its lead candidate, VK2735, is a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, being developed in both subcutaneous (injectable) and oral formulations.
The company is advancing a broad metabolic pipeline, including VK3019, an amylin receptor agonist, and VK2809, an oral thyroid hormone receptor beta agonist for metabolic and liver disease. Because VK2735 is positioned against established incretin therapies from Eli Lilly (LLY) and Novo Nordisk (NVO), investors closely track its clinical readouts and financing activity.
Viking Therapeutics (VKTX) Stock Price Performance: Last 30 Days vs. Quarter
Over the trailing 30 days, VKTX moved from a closing level near $28.99 to approximately $25.45, a decline of roughly 12%. The move was not linear: shares spiked 35.7% to $40.85 on September 22 after the maintenance-dosing results, then gave back those gains as the company announced and closed a dilutive financing.
The broader quarterly picture is more pronounced. Measured from a closing level near $37 in mid-July, the stock has fallen roughly 31%, reflecting a sharp but ultimately temporary rally that unwound amid new share issuance and ongoing competitive pressure in the obesity market.
What Drove VKTX Stock Price in the Last 30 Days
The dominant catalyst was the September 22 release of positive Part 1 results from a maintenance-dosing study of subcutaneous VK2735. Participants who switched to every-other-week dosing retained up to 97% of their prior weight loss, while those moved to monthly dosing retained up to 90%, versus 61% for placebo. A group continuing weekly 17.5 mg dosing reached 21.7% weight loss by week 33 with no plateau observed, and gastrointestinal side effects during maintenance were comparable to placebo.
The readout triggered a 35.7% single-day surge, the stock's largest one-day gain in more than two years. Truist analysts described the data as a "best-case scenario" and reiterated a Buy rating with an $83 price target, while Leerink Partners called the tolerability profile "impressively clean."
The rally was quickly reversed by financing news. On September 24, Viking priced an upsized public offering of 7,857,143 common shares at $35.00 per share alongside $225 million of 2.00% convertible senior notes due 2032. The deal, initially announced at $400 million, was increased to $500 million and ultimately closed on September 28 with gross proceeds of approximately $575 million, including full exercise of over-allotment options. The issuance of new shares below the recent spike diluted existing holders and weighed heavily on the stock.
What Drove VKTX Stock Performance Over the Last Quarter
Across the trailing quarter, VKTX has been driven by the tension between strong clinical data and persistent dilution. Shares traded near $37 in mid-July, and the September maintenance-dosing readout briefly validated VK2735's differentiated profile. However, the subsequent capital raise reset investor expectations around share count and near-term fundamentals.
Viking has continued to expand its pipeline, initiating Part 2 of the VK2735 maintenance study on October 6 to evaluate oral and subcutaneous maintenance regimens, and launching the Phase 3 SUNRISE program for oral VK2735 on October 14. These developments reinforce the company's long-term strategy, but the quarterly price action has remained dominated by the financing overhang and broader biotech sector volatility.
Trending AI Robots
Investors tracking fast-moving stocks like VKTX often turn to automated tools for signal-based analysis. Tickeron's Trending AI Robots page showcases a curated selection of AI-driven trading bots. While Tickeron offers hundreds of bots trading thousands of tickers, only the top-performing and most relevant strategies appear in this section. The bots vary widely in strategy, timeframe, and performance metrics, allowing traders to compare approaches suited to different market conditions. Exploring the Trending AI Robots section can help investors discover data-driven tools to complement their own research.
VKTX Stock Forecast Drivers: What Investors Should Watch Next
Looking ahead, the primary value driver remains VK2735. Key milestones include the continued enrollment and execution of the Phase 3 VANQUISH-1 and VANQUISH-2 subcutaneous studies, the Phase 3 SUNRISE program for oral VK2735, and Part 2 results from the maintenance study, which the company expects in 2027.
Investors should also monitor competitive developments from Lilly and Novo Nordisk, regulatory and safety updates across the incretin class, and the company's cash position following its recent financing. Macroeconomic conditions, biotech sector sentiment, and any additional capital-raising activity are likely to remain relevant to share performance. As a clinical-stage company with no approved products, Viking's valuation remains highly sensitive to clinical outcomes and trial timelines.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
VKTX in downward trend: 10-day moving average moved below 50-day moving average on October 06, 2026
The 10-day moving average for VKTX crossed bearishly below the 50-day moving average on October 06, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on VKTX as a result. In 75 of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 85%.
The Moving Average Convergence Divergence Histogram (MACD) for VKTX turned negative on October 01, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In 40 of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at 80%.
VKTX moved below its 50-day moving average on September 28, 2026 date and that indicates a change from an upward trend to a downward trend.
The 50-day moving average for VKTX moved below the 200-day moving average on October 07, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VKTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
VKTX broke above its upper Bollinger Band on September 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for VKTX entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where VKTX's RSI Oscillator exited the oversold zone, 29 of 38 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 76%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 55 of 67 cases where VKTX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.
Following a +38.33% 3-day Advance, the price is estimated to grow further. Considering data from situations where VKTX advanced for three days, in 235 of 281 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 16 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 68 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.440) is normal, around the industry mean (2.973). P/E Ratio (-5.225) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 77 (best 1 - 100 worst), indicating slightly worse than average price growth. VKTX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 82 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VKTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company that engages in the development of therapies for metabolic and endocrine disorders
Industry Biotechnology